Johnson & Johnson Stock

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-06-10 pm EDT 5-day change 1st Jan Change
147.1 USD +0.03% Intraday chart for Johnson & Johnson -0.41% -6.13%
Sales 2024 * 88.79B Sales 2025 * 92.1B Capitalization 354B
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 3.99 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 3.84 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 131,900
Yield 2024 *
3.28%
Yield 2025 *
3.42%
Free-Float 77.08%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.01%
1 week-0.41%
Current month+0.31%
1 month-1.85%
3 months-7.77%
6 months-4.72%
Current year-6.13%
More quotes
1 week
144.66
Extreme 144.66
148.30
1 month
143.71
Extreme 143.71
154.86
Current year
143.13
Extreme 143.13
163.58
1 year
143.13
Extreme 143.13
175.97
3 years
143.13
Extreme 143.13
186.69
5 years
109.16
Extreme 109.16
186.69
10 years
81.79
Extreme 81.79
186.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 88-12-31
Director of Finance/CFO 57 97-12-31
Chief Tech/Sci/R&D Officer 58 19-11-04
Members of the board TitleAgeSince
Director/Board Member 70 19-04-24
Director/Board Member 72 14-06-18
Director/Board Member 70 09-10-21
More insiders
Date Price Change Volume
24-06-10 147.1 +0.03% 5,751,309
24-06-07 147.1 +0.45% 5,111,626
24-06-06 146.4 +0.31% 5,016,301
24-06-05 146 -1.24% 5,891,299
24-06-04 147.8 +0.04% 8,876,441

Delayed Quote Nyse, June 10, 2024 at 04:00 pm EDT

More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
147.1 USD
Average target price
171.7 USD
Spread / Average Target
+16.71%
Consensus